Incyte Corp (INCY) Stock Analysis
Verdict: HOLD
Jakafi cash flow funds pipeline growth, but the 2029 patent cliff and minimal $130 consensus target cap upside near $125.69.
Investment score: 63/100
Analysis as of
Is Incyte Corp stock worth reviewing? The TradeMates thesis
Incyte exhibits high profitability and top-tier balance sheet strength, but near-term valuation upside appears capped ahead of a steep post-2028 patent cliff.
7-factor investment score
- Valuation: 58/100 (weight 20%)
- Financial Health: 88/100 (weight 15%)
- Technical Momentum: 72/100 (weight 15%)
- Earnings Quality: 78/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 52/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Incyte Corp opportunities and risks
What speaks for INCY
- Pipeline expansion with Minjuvi and Pemazyre broadening commercial reach
What speaks against INCY
- Jakafi loss of exclusivity creates a severe revenue cliff in 2029
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| INCY | 15.5x | 4.4x | 10.5x | 92.6% | 27.7% | 7.5% |
| NTRA | n/a | 18.9x | n/a | 65.3% | -7.1% | 0.1% |
| RVMD | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.7% |
| ALNY | 39.4x | 6.7x | 27.6x | 79.7% | 16.8% | 1.7% |
| BIIB | 38.0x | 3.2x | 23.3x | 67.7% | 8.4% | 9.3% |
| INSM | n/a | 23.8x | n/a | 83.3% | -76.9% | -3.1% |
| Peer median | n/a | 6.7x | n/a | 67.7% | 0.0% | 0.1% |
Frequently asked questions about Incyte Corp (INCY)
Is INCY stock a good investment?
The TradeMates model rates Incyte Corp as HOLD with an investment score of 63/100. Incyte exhibits high profitability and top-tier balance sheet strength, but near-term valuation upside appears capped ahead of a steep post-2028 patent cliff. This is algorithmic model output, not personal investment advice.
Is INCY stock a buy?
The TradeMates model verdict for INCY is HOLD with an investment score of 63/100. Treat this as a model signal to review, not a personal buy recommendation.